Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

221. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. (Abstract)

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Persistent use of glucocorticoid drugs is associated with bone loss and increased fracture risk. Concurrent oral bisphosphonates increase bone mineral density and reduce frequency of vertebral fractures, but are associated with poor compliance and adherence. We aimed to assess whether one intravenous infusion (...) of zoledronic acid was non-inferior to daily oral risedronate for prevention and treatment of glucocorticoid-induced osteoporosis.This 1-year randomised, double-blind, double-dummy, non-inferiority study of 54 centres in 12 European countries, Australia, Hong Kong, Israel, and the USA, tested the effectiveness of 5 mg intravenous infusion of zoledronic acid versus 5 mg oral risedronate for prevention and treatment of glucocorticoid-induced osteoporosis. 833 patients were randomised 1:1 to receive zoledronic

2009 Lancet Controlled trial quality: predicted high

222. Zoledronic acid (Aclasta) - Treatment of osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture.

Zoledronic acid (Aclasta) - Treatment of osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture. Published 12 January 2009 Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail rosie.murray@nhs.net Chairman Dr Kenneth R Paterson Scottish Medicines Consortium zoledronic acid 5mg/100ml solution for infusion (Aclasta ® ) (No. 535/08) Novartis Pharmaceuticals UK Ltd Statement of Advice 05 (...) December 2008 ADVICE: in the absence of a submission from the holder of the marketing authorisation. zoledronic acid 5mg (Aclasta ® ) is not recommended for use within NHSScotland for the treatment of osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context

2009 Scottish Medicines Consortium

223. Incorporating adherence into health economic modelling of osteoporosis Full Text available with Trip Pro

Incorporating adherence into health economic modelling of osteoporosis Incorporating adherence into health economic modelling of osteoporosis Incorporating adherence into health economic modelling of osteoporosis Strom O, Borgstrom F, Kanis JA, Jonsson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the impact of adherence on the cost-effectiveness of drugs for patients with osteoporosis. The authors concluded that improved adherence led to relevant benefits, but that these might be offset by increased intervention costs. The study appears to have been based on valid methodology, but the data sources were only partially reported. In general, the authors’ conclusions appear to be valid. Type of economic

2009 NHS Economic Evaluation Database.

224. Using the osteoporosis self-assessment tool for referring older men for bone densitometry: a decision analysis

Using the osteoporosis self-assessment tool for referring older men for bone densitometry: a decision analysis Using the osteoporosis self-assessment tool for referring older men for bone densitometry: a decision analysis Using the osteoporosis self-assessment tool for referring older men for bone densitometry: a decision analysis Ito K, Hollenberg JP, Charlson ME Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the cost-effectiveness of universal versus selective, using the Osteoporosis Self-Assessment Tool (OST), bone densitometry for the diagnosis of osteoporosis. The authors concluded that using the OST, followed by bone densitometry for those with an OST score of -2 or less, and then alendronate treatment

2009 NHS Economic Evaluation Database.

225. Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial

Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

226. Risk factor assessment for osteoporosis and/or increased fracture risk in men.

Risk factor assessment for osteoporosis and/or increased fracture risk in men. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding

2008 University of Texas at Austin School of Nursing, Family Nurse Practitioner Program

227. A once yearly IV infusion of zoledronic acid prevented fractures in postmenopausal women with osteoporosis

A once yearly IV infusion of zoledronic acid prevented fractures in postmenopausal women with osteoporosis A once yearly IV infusion of zoledronic acid prevented fractures in postmenopausal women with osteoporosis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A once yearly IV infusion of zoledronic acid prevented fractures in postmenopausal women with osteoporosis Article Text Therapeutics A once yearly IV infusion of zoledronic acid

2008 Evidence-Based Medicine

228. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. (Abstract)

Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. The American College of Physicians (ACP) developed this guideline to present the available evidence on various pharmacologic treatments to prevent fractures in men and women with low bone density or osteoporosis.Published literature on this topic was identified by using MEDLINE (1966 to December 2006), the ACP Journal Club database (...) , the Cochrane Central Register of Controlled Trials (no date limits), the Cochrane Database of Systematic Reviews (no date limits), Web sites of the United Kingdom National Institute of Health and Clinical Excellence (no date limits), and the United Kingdom Health Technology Assessment Program (January 1998 to December 2006). Searches were limited to English-language publications and human studies. Keywords for search included terms for osteoporosis, osteopenia, low bone density, and the drugs listed

2008 Annals of Internal Medicine

229. Zoledronic acid - osteoporosis

Zoledronic acid - osteoporosis Common Drug Review CEDAC Meeting – April 16, 2008; CEDAC Reconsideration – June 18, 2008 Page 1 of 3 Notice of CEDAC Final Recommendation – June 25, 2008 © 2008 CADTH CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION ZOLEDRONIC ACID (Aclasta ™ – Novartis Pharmaceuticals Canada Inc.) Description: Zoledronic acid, an injectable bisphosphonate agent that inhibits osteoclast-mediated bone resorption, is marketed as Aclasta ™ and Zometa ™ (...) . Aclasta is approved for the treatment of osteoporosis in post- menopausal women to reduce the incidence of hip, vertebral and non-vertebral fractures and for the treatment of Paget’s disease of the bone. Zometa is approved for tumour induced hypercalcemia, bone metastases from solid tumours and osteolytic lesions of multiple myeloma. This submission to the Common Drug Review was for the treatment of osteoporosis in post-menopausal women. Dosage Forms: 5 mg/100 mL solution for intravenous infusion

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

230. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial (Abstract)

Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial We aimed to compare the effect of risedronate (RIS) and teriparatide (TPTD) (recombinant human parathyroid hormone 1-34) on bone turnover markers in women with postmenopausal osteoporosis.Forty-four Caucasian women (age 65.1 +/- 1.6 years) with postmenopausal osteoporosis were randomly assigned to receive either RIS 35 mg once weekly (n = 22) or TPTD 20 (...) ) and increased in TPTD group (p < 0.001) throughout the treatment. iPTH increased significantly in RIS group (p < 0.05) and decreased in TPTD group (p < 0.001). Finally, lumbar spine BMD increased significantly in both RIS (p = 0.003) and TPTD groups (p < 0.001) without significant differences between them.Our data suggest that both serum P1NP and CTx are reliable markers of RIS and TPTD action in women with postmenopausal osteoporosis. In a similar way, serum total ALP can be used as an alternative marker

2008 EvidenceUpdates Controlled trial quality: uncertain

231. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. (Abstract)

Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. The American College of Physicians developed this guideline to present the available evidence on risk factors and screening tests for osteoporosis in men.Published literature on this topic was identified by using MEDLINE (1990 to July 2007). Reference mining was done on the retrieved articles, references of previous reviews, and solicited articles from experts. The inclusion criteria (...) for the studies were measuring risk factors for low bone mineral density or osteoporotic fracture in men or comparing 2 different methods of assessment for the presence of osteoporosis in men. This guideline grades the evidence and recommendations by using the American College of Physicians' clinical practice guidelines grading system. RECOMMENDATION 1: The American College of Physicians recommends that clinicians periodically perform individualized assessment of risk factors for osteoporosis in older men

2008 Annals of Internal Medicine

232. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Full Text available with Trip Pro

Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Little information is available on the comparative effectiveness of osteoporosis pharmacotherapies.To compare the relative effectiveness of osteoporosis treatments to reduce nonvertebral fracture risk among older adults.Cohort study.Enrollees in 2 statewide pharmaceutical benefit programs for persons age 65 years or older.43,135 new recipients of oral bisphosphonates, nasal calcitonin, and raloxifene who began

2008 Annals of Internal Medicine

233. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Full Text available with Trip Pro

Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Osteoporosis is diagnosed by the measurement of bone mineral density, which is a highly heritable and multifactorial trait. We aimed to identify genetic loci that are associated with bone mineral density.In this genome-wide association study, we identified the most promising of 314 075 single nucleotide polymorphisms (SNPs) in 2094 women in a UK study. We then tested these SNPs for replication (...) protein) gene. A non-synonymous SNP in the LRP5 gene was associated with decreased bone mineral density (rs3736228, p=6.3x10(-12) for lumbar spine and p=1.9x10(-4) for femoral neck) and an increased risk of both osteoporotic fractures (odds ratio [OR] 1.3, 95% CI 1.09-1.52, p=0.002) and osteoporosis (OR 1.3, 1.08-1.63, p=0.008). Three SNPs near the TNFRSF11B gene were associated with decreased bone mineral density (top SNP, rs4355801: p=7.6x10(-10) for lumbar spine and p=3.3x10(-8) for femoral neck

2008 Lancet

234. Management and prevention of osteoporosis.

Management and prevention of osteoporosis. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline Clearinghouse (NGC

2008 Michigan Quality Improvement Consortium

235. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International (Abstract)

A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International To compare alendronate 70 mg once weekly (OW) with risedronate 35 mg OW with respect to change in bone mineral density (BMD), biochemical markers and upper gastrointestinal (UGI) tolerability over 24 months.This was a 12-month extension to the Fosamax Actonel Comparison Trial international study (FACTS). Postmenopausal women (...) with osteoporosis randomly assigned to either alendronate 70 mg OW or risedronate 35 mg OW for the 12-month base study continued taking the same double-blind study medication. Efficacy measurements were BMD at the hip trochanter, lumbar spine, total hip, and femoral neck and levels of four bone turnover markers at 24 months. The primary hypothesis was that alendronate would produce a greater mean per cent increase from baseline in hip trochanter BMD at 24 months.Trochanter BMD increased significantly from

2008 EvidenceUpdates Controlled trial quality: uncertain

236. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. Full Text available with Trip Pro

Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. Mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) gene cause rare syndromes characterized by altered bone mineral density (BMD). More common LRP5 variants may affect osteoporosis risk in the general population.To generate large-scale evidence on whether 2 common variants of LRP5 (Val667Met, Ala1330Val) and 1 variant of LRP6 (Ile1062Val) are associated with BMD and fracture (...) affected BMD. The LRP6 Ile1062Val polymorphism was not associated with any osteoporosis phenotype. All aforementioned associations except that between Val1330 and all fractures and vertebral fractures remained significant after multiple-comparison adjustments.Common LRP5 variants are consistently associated with BMD and fracture risk across different white populations. The magnitude of the effect is modest. LRP5 may be the first gene to reach a genome-wide significance level (a conservative level

2008 JAMA

237. Therapeutic Brief 15 - osteoporosis: strategies to minimise fracture risk

Therapeutic Brief 15 - osteoporosis: strategies to minimise fracture risk Therapeutic Brief 15 – Osteoporosis: strategies to minimise fracture risk. June 2008. Veterans’ Medicines Advice and Therapeutics Education Services Osteoporosis: strategies to minimise fracture risk Key points Osteoporosis is preventable and treatable. Evidence from clinical trials suggests that available therapies reduce the risk of fractures by as much as 30 - 50%. Consider BMD testing in high risk patients including (...) those aged over 50 years who have had a low trauma fracture and those aged 70 years and over. Ensure adequate calcium and vitamin D, as these are the cornerstone of any regimen aimed at preventing or treating osteoporosis. Consider specific antiresorptive drugs for patients with very low bone density (T-score = -3.0) Consider specific antiresorptive drugs after low trauma fracture associated with low bone density to prevent further bone loss and reduce fracture risk. Recommend strategies to prevent

2008 Clinical Practice Guidelines Portal

238. How do you approach male patients with osteoporosis?

How do you approach male patients with osteoporosis? How do you approach male patients with osteoporosis? – Clinical Correlations Search How do you approach male patients with osteoporosis? February 28, 2008 5 min read Commentary by Carrie Mahowald MD Case: GS, a 65 year old man with only a history of severe OA, is seen in pre-op clinic for medical clearance before his hip replacement. On his pre-op x-ray, an incidental finding of a lumbar vertebral compression fracture is noted. After his hip (...) replacement, how would you work him up for osteoporosis? Osteoporosis, defined as low bone mass and the deterioration of bone micro-architecture which leads to the compromise of bone strength and the increased risk of fracture, is the most common bone disease in humans. Osteoporosis affects millions of people and the risk increases with increasing age causing significant mortality and morbidity including chronic pain, disability and death. Osteoporosis in men is less common than in women and therefore

2008 Clinical Correlations

239. FRAX: A Brand New Tool For the Management of Osteoporosis

FRAX: A Brand New Tool For the Management of Osteoporosis FRAX: A Brand New Tool For the Management of Osteoporosis – Clinical Correlations Search FRAX: A Brand New Tool For the Management of Osteoporosis August 13, 2008 4 min read Commentary by Judith Brenner MD, Associate Editor, Clinical Correlations. Reviewed by Valerie Peck MD, NYU Division of Endocrinology. An 81 year old Caucasian woman with a history of diabetes and hypertension who was admitted to the orthopedic service with a hip (...) fracture after falling in her home. This is a typical story and represents the end stages of osteoporosis. It is the myocardial infarction of the bone world. Like cardiovascular disease, prevention and identification of at-risk individuals is the most powerful tool clinicians have available to make an impact and prevent outcomes such as these. The questions we face are: Who is most at risk? When do we intervene? What is our intervention? So, how do we quantify risk? Up until now, it has essentially

2008 Clinical Correlations

240. Teriparatide (Forsteo®) for the treatment of osteoporosis in men at increased risk of fracture

Teriparatide (Forsteo®) for the treatment of osteoporosis in men at increased risk of fracture Teriparatide (Forsteo®) for the treatment of osteoporosis in men at increased risk of fracture Teriparatide (Forsteo®) for the treatment of osteoporosis in men at increased risk of fracture All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation All Wales Medicines Strategy Group (AWMSG). Teriparatide (Forsteo®) for the treatment of osteoporosis in men at increased risk of fracture. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2108. 2008 Authors' conclusions Teriparatide (Forsteo®) is not recommended for use within NHS Wales for the treatment of osteoporosis in men at increased risk of fracture

2008 Health Technology Assessment (HTA) Database.